

## PUBLICATIONS:

### BOOK Chapter

Non-Viral Delivery Systems in Gene Therapy and Vaccine Development. Azam Bolhassani and Sima Rafati. INTECH, OPEN ACCESS PUBLISHER. University Campus

### ARTICLES

1. Saljoughian N, Taheri T, Zahedifard F, Taslimi Y, Doustdari F, Doroud D, Azizi H, Heidari K, Vasei M, Namvar N, Papadopoulou B, Rafati S. **Live nonpathogenic Leishmania expressing selected immunodominant parasite antigens elicit protective immunity against visceral leishmaniasis in mice.**(PLOS Neglected Tropical Diseases. 2013, submitted)
2. Bolhassani A, Rafati S. **Mini-chaperones: Potential immuno-stimulators in vaccine design.**(Hum Vaccin Immunother. 2012 Oct 29;9(1)).
3. Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F **Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.**(Immunol Lett. 2012 17.: S0165- 2478(12)00215-5)
4. Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A, Rafati S. **Recombinant *Leishmania tarentolae* Encoding the Human papillomavirus Type 16 E7 Gene in Tumor Mice Model.** (Immunotherapy. 2012 Nov;4(11):1107-20)
5. Mohit E, Rafati S. **Chemokine-based Immunotherapy: Delivery systems and combination therapies, Review** ( Immunotherapy. 2012, 4 (8) 1-34)
6. Mohit E, Bolhassani A, Zahedifard F, Seyed N, Eslamifar A, Taghikhani M, Samimirad K, Rafati S. **Enhancement of DNA vaccine potency by covalent linkage to Gp96, co-administration of IP-10 and PEI600-Tat delivery system against HPV infections.** (Mol Immunol. 2013 ,53(1-2):149-60)
7. Doroud D, Rafati S. **Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.** (Expert Rev, 2012;75(1)27-37)

8. Stäger S, Rafati S. **CD8(+) T cells in leishmania infections: friends or foes?**(Front Immunol. 2012;3:5)
9. Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S. **The Contribution of NT-gp96 as an Adjuvant for Increasing HPV16 E7-Specific Immunity in C57BL/6 Mouse Model.**(Scand J Immunol,2012;75(1):27-37)
10. Bolhassani A, Safaiyan S, Rafati S. **Improvement of different vaccine delivery systems for cancer therapy.**(Mol Cancer. 2011 Jan 7;10:3)
11. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Rafati S. **Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice.**(Parasite Immunol. 2011 Jun;33(6):335-48) .
12. Amani J, Mousavi SL, Rafati S, Salmanian AH. **Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice.**(Plant Sci. 2011;180(4):620-7)
13. Mizbani A, Taslimi Y, Zahedifard F, Taheri T, Rafati S. **Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae.**( Parasitol Res, 2011;109(3):793-9)
14. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, Vahabpour R, Torkashvand F, Vaziri B, Rafati S. **Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection.**(J Control Release, 2011: 30;153(2):154-62)
15. Doroud D, Zahedifard F, Vatanara A, Taslimi Y, Vahabpour R, Torkashvand F, Vaziri B, Rouholamini Najafabadi A, Rafati S. **C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.**(PlosNegl Trop Dis,2011:5(7)1236)
16. Safaiyan S, Bolhassani A, Nylen S, Akuffo H, Rafati S. **Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection.** (Parasite Immunol, 2011;33(11):609-20)
17. McDowell MA, Rafati S, Ramalho-Ortigao M, Ben Salah A. **Leishmaniasis Middle East and North Africa research and development priorities.**(PlosNegl Trop Dis,2011:5(7)1219)
18. Mehrizi A.A, Zakeri S, Rafati S, Salmanian A.H, Djadid N.D. **Immune responses elicited by co-immunization of Plasmodium vivax and P.falciparum MSP-1 using prime-boost immunization strategies.**(ParasiteImmunol,2011:33(11):594-608)

19. Seyed N, Zahedifard F, Safaiyan SH, Gholami E, Doustdari F, Azadmanesh K, Mirzaei M, Eslami N, KhademSadegh A, Eslami far A, Sharifi I, Rafati S. **In Silico Analysis of Six Known Leishmania major Antigens and In Vitro Evaluation of Specific Epitopes Eliciting HLA-A2 Restricted CD8 T Cell Response.**(PlosNegl Trop Dis,2011:5(9)1295)
20. Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S. **Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against *L.major* infection in susceptible BALB/c Mice and its antigenic properties in human *Leishmania*.**(Experimental Parasitology, 2011:127(3)627-36)
21. Bolhassani A, Gholami E, Zahedifard F, moradin N, Parsi P, Doustdari F, Papadoulou B, Rafati S. **Enhancement of DNA vaccine potency by fusion of HSV-1VP22 and EGFP to *Leishmania major* amastin antigen in BALB/c mice model.** (Experimental Parasitology, 2011:128(1):9-17)
22. Bolhassani A, Taheri T, Taslimi Y, Zamanlui S, Zahedifard F, Seyed N, Torkashvand F, Vaziri B, Rafati S. **Fluorescent *Leishmania* species: Development of stable GFP expression and its application for in vitro and in vivo studies.** (Experimental Parasitology, 2011:127(3):637-45)
23. Amani J., Salmanian A.H., Rafati S., Mousavi SL. **Immunogenic Properties of chimeric protein from espA, eae and tir genes of *Escherichia coli* O157:H7.** (Vaccine, 2010:28(42):6923-9 )
24. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Gholami E, Rafati S. **Cationic solid lipid nanoparticles loaded by cysteine proteinase Genes as a Novel anti-leishmaniasis DNA vaccine Delivery system: characterization and in vitro evaluation.** (Journal of pharmacy and pharmaceutical science, 2010, 13(3) 320-335)
25. Taheri T., Salmanian A., Gholami E., Doustdari F., Zahedifard F., Rafati S. **Disruption of *Leishmania major* signal peptidase type I and its consequences in survival, growth and infectivity rate of parasite.** (Experimental Parasitology, 2010 (126)135-145)
26. Mizbani A., Taheri T., Zahedifard F., Taslimi Y., Azizi H., Azadmanesh K., Papadoulou B., Rafati S. **Recombinant *Leishmania tarentolae* expressing the A2 Virulence gene as a novel candidate Vaccine against Visceral Leishmaniasis.** (Vaccine 28 (2010) 53-62)
27. Bolhassani A., Zahedifard F., Taslimi Y., Taghikhani. M, Nahavandian B., Rafati S. **Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients.** (Indian J Med Res. 2009 Nov;130(5):533-41)
28. Arashkia A., Roohvand F., Memarnejadian A., Aghasadeghi MR., Rafati S. **Construction of HCV-polypeptide vaccine candidates harboring immune-enhancer sequences and**

**primary evaluation of their immunogenicity in BALB/c mice.**(Virus Genes. 2010 40(1):44-52)

- 29.** Amani J., Mousavi SL., Rafati S. Salmanian A.H., **In silico analysis of chimeric espA, eae and tir fragments of *Escherichia coli* O157:H7 for oral immunogenic applications.** (TheorBiol Med Model. 2009 ;8;6:28)
- 30.** Bolhassani A., Mohit E., Rafati S. **Different spectra of therapeutic vaccine development against HPV infections.**( Human Vaccines2009, 5:10, 1-18)
- 31.** Bolhassani A. and Rafati S. **DNA Immunization as an Efficient Strategy for Vaccination.** (Avicenna Journal of Medical Biotechnology, 2009 vol.1, No2)
- 32.** Azizi H., Hassani K.,Taslimi Y., ShateriNajafabadi H., Papadopoulou B., Rafati S. **Searching for virulence factors in the non-pathogenic parasite to humans *Leishmania tarentolae*.** (Parasitology, 2009; 136: 723-735)
- 33.** Bolhassani A., Ghasemi N., Servis C., Taghikhani M. and Rafati S. **The Efficiency of a Novel Delivery System (PEI600-Tat) in Development of Potent DNA Vaccine Using HPV16 E7 as a Model Antigen.** (Drug Delivery, 2009; 16(4):196-204)
- 34.** Salhi A, Rodrigues, Santoro F, Dessein H, Romano A, Castellano L.R, Mathieu Sertorio, Rafati S, Chevillard C, Prata A, Alcaï's, Laurent Argiro A, Dessein A. **Immunological and Genetic Evidence for a Crucial Role of IL-10 in Cutaneous Lesions in Humans Infected with *Leishmania braziliensis*.** (J. Immunology, 2008; 180(9):6139-48.
- 35.** Bolhassani A., Taghikhani M., Ghasemi N., Soleimanjahi H., Rafati S. **Comparison of Two Delivery Systems Efficiency by Using Poly ethylenimine (PEI) for Plasmid HPV16E7 DNA Transfection into COS-7 Cells.** (Modarres Journal of Medical Sciences, 2008 Vol.11, No 1&2)
- 36.** Memarnejadian A., Roohvand F., Arashkia A., Rafati S., Shokrgozar MA., **Polytope DNA vaccine development against hepatitis C virus: A stream-lined approach from *in silico* design to *in vitro* and primary *in vivo* analyses in BALB/c mice.** (Protein & peptide letters, 2009 16(7):842-50)
- 37.** Bolhassani A., Rafati S. **Heat-shock proteins as powerful weapons in vaccine development.** (Expert Rev Vaccines, 2008; 7(8):1185-99, Review)
- 38.** Abtahi H., Salmanian A.H., Rafati S., Nejad GB., Saffari M., Ghazavi A., Mosayebi G. **The profile of cytokines and IgG subclasses in BALB/c mice after immunization with *Brucella* ribosomal gene.** (Pak J BiolSci, 2008;11(21): 2472-7)

39. Bolhassani A., Zahedifard F., Taghikhani M., Rafati S. **Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.**(Vaccine, 2008; 26(46):5822-9)
40. Rafati S., Zahedifard F., KakehAzari M., Taslimi Y., Taheri T. **C-terminal Extension of cysteine proteinase type I is responsible for TH2 elicitation in experimental murine *L. infantum* infection.** (Experimental Parasitology, 2008;118: 393-401)
41. Golkar M., Rafati S., Abdel-Latif MS., Brenier-Pinchart MP., Fricker-Hidalgo H., Sima BK., Babaie J., Pelloux H., Cesbron-Delauw MF., Mercier C. **The dense granule protein GRA2, a new marker for the serodiagnosis of acute *Toxoplasma* infection: comparison of sera collected in both France and Iran from pregnant women.** (DiagnMicrobiol Infect Dis, 2007;58(4):419-26)
42. Golkar M., Shokrgozar MA., Rafati S., Musset K., Assmar M., Sadaie R., Cesbron-Delauw MF. andMercier C. **Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against *Toxoplasma* chronic infection in mice.** (Vaccine,2007;25 (21):4301-11)
43. Balenga NA., Rafati S. **Innate immune system: Specific or non-specific?** (Med Hypotheses,2007;69(2):460-1)
44. Rafati S., Gholami E., Hassani N., Ghaemimanesh F., Taslimi Y., Taheri T., Soong L. ***Leishmania major* heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.** (Vaccine, 2007;25(21) :4159-69)
45. Rafati S., Hassani N., Taslimi Y., Movassagh H., Rochette A., Papadopoulou B. **Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis.** (Clin Vaccine Immunol, 2006;13(10):1104-10)
46. Khamesipour A., Rafati S., Davoudi N., Maboudi F., Modabber F. **Leishmaniasis vaccine candidates for development: a global overview.** (Indian J Med Res,2006;123(3):423-38. Review)
47. Balenga NA., Zahedifard F., Weiss R., Sarbolouki MN., Thalhamer J., Rafati S. **Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy.**(J Biotechnol, 2006;124(3):602-14)
48. Rafati S., Ghaemimanesh F., Zahedifard F. **Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against *Leishmania major* infection using Signal Peptidase type I in BALB/c mice.** (Vaccine, 2006;24(16):3290-7)

49. Rafati S., Zahedifard F., Nazgouee F. **Prime-boost vaccination using cysteine proteinases type I and II of *Leishmania infantum* confers protective immunity in murine visceral leishmaniasis.** (Vaccine, 2006;24(12):2169-75)
50. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., Sanos S., Kaye P., Taghikhani M., Jamshidi S. and Rad MA. **Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of *L. infantum*.** (Vaccine, 2005;23(28):3716-25)
51. Nakhaee A., Rafati S., Salmanian A.H., Taghikhani M., Mohebbali M., Taheri T. **Immunological responses of naturally infected dogs to Type I and Type II recombinant cysteine proteinases of *Leishmania infantum*.**(Moddars J. of Medical Sciences, 2005;8(1):55-66)
52. Golkar M., Shokrgozar M.A., Rafati S., Sadaie M.R., and Assmar M. **Construction, expression and preliminary immunological evaluation of a DNA plasmid encoding the GRA2 protein of *Toxoplasma gondii*.**(Iranian Biomedical Journal,2005;9(1):1-8)
53. Rafati S., Salmanian A.H., Taheri T., Masina S., Schaff C., Taslimi Y. and Fasel N. **Type I signal peptidase from *Leishmania* is a target of the immune response in human cutaneous and visceral leishmaniasis.**(MolBiochemParasitol,(2004; 135(1):13-20)
54. Zadeh-Vakili A., Taheri T., Taslimi Y., Doustdari F., Salmanian A.H. and Rafati S. **Immunization with the hybrid protein vaccine, consisting of *Leishmania major* cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.**(Vaccine,2004;22(15-16):1930-40)
55. Zadeh-Vakili A., Taheri T., Taslimi Y., Doustdari F., Salmanian A.H., Rafati S. **Bivalent DNA vaccination with genes encoding *Leishmania major* cysteine proteinases type I and type II protects mice against infectious challenge.** (Iranian Journal of Biotechnology, 2004;2(1):10-15)
56. Nakhaee A., Taheri T., Taghikhani M., Mohebbali M., Salmanian A.H., Fasel N., Rafati S. **Humoral and cellular immune responses against Type I cysteine proteinase of *Leishmania infantum* are higher in asymptomatic than symptomatic dogs selected from a naturally infected population.**(Vet Parasitol,2004;119(2-3):107-23)
57. Abtahi H., Salmanian AH., Rafati S., BehzadianNejad G. Hassan ZM. **High level expression of recombinant ribosomal protein (L7/L12) from *Brucella abortus* and its reaction with infected human sera.** (Iranian Biochemical Journal 2004;8(1): 13-18)
58. Golkar M., Rafati S., Taslimi Y., Taheri T. Doustdary F. and Assmar M. **High-level expression and evaluation the M. High-level expression and evaluation the antigenicity of a recombinant *Toxoplasma gondii* GRA2 protein.** (Iranian Journal of Biotechnology, 2004;2(3))

59. Rafati S., Fasel N. Masina S. ***Leishmania* cysteine proteinases: from gene to putative subunit vaccine.**( Review, Current Genomic. 2003; 4:109-121)
60. Mahmoodi M., Khamesipour A., Dowlati Y., Rafati S., Momeni AZ., Emamjomeh M., Hejazi H. and Modabber F. **Immune response measured in human volunteers vaccinated with autoclaved *Leishmania major* vaccine mixed with low dose of BCG.** (ClinExpImmunol. 2003;134(2):303-8)
61. Rafati S., Nakhaee A., Taheri T., Ghashghaii A., Salmanian AH., Jimenez M., Mohebbali M., Masina S. and Fasel N. **Expression of cysteine proteinase type I and II of *Leishmania infantum* and their recognition by sera during canine and human visceral leishmaniasis.**( ExpParasitol.2003;103(3-4):143-51)
62. Pascalis H., Lavergne A., Bourreau E., Prévot-Linguet G., Kariminia A., Pradinaud R., Rafati S. and Launois P. **Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to *Leishmania guyanensis*.** (Infect Immun. 2003;71(5):2924-6)
63. Farzaneh P., Ebtekar M., Hassan ZM. and Rafati S. **Murine cytokine patterns following rubella vaccination.** (Iran J Allergy Asthma Immunol. 2003;2(2):89-93)
64. Rafati S., Kariminia A., Seyde-Eslami S., Narimani M., Taheri T. Lebbatard M. **Recombinant cysteine proteinases-based vaccines against *Leishmania major* in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation.** (Vaccine. 2002;20(19-20):2439-47)
65. Rafati S., Salmanian A.H., Taheri T., Vafa M. and Fasel N. **A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of *Leishmania major*.**(Vaccine. 2001;19(25-26):3369-75)
66. Rafati S., Salmanian A.H., Hashemi K., Schaff C., Belli S. Fasel N. **Identification of *Leishmania major* cysteine proteinases as targets of the immune response in humans.** (MolBiochemParasitol, (2001;113(1):35-43)
67. Rafati S., Abraham Baba A., Bakhshayesh M. and Vafa M. **Vaccination of BALB/c mice with *Leishmania major* mastigote-specific cysteine proteinase.**(ClinExpImmunol. 2000;120(1):134-8)
68. Solioz N., Blum-Tirouvanziam U., Jacquet R., Rafati S., Corradin G., Mauël J. Fasel N. **The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis.** (Vaccine. 1999;18(9-10):850-9)

- 69.** Rafati S., Couty-Jouve S., Alimohammadian M.H. Louis JA. **Biochemical analysis and immunogenicity of *Leishmania major* amastigote fractions in cutaneous leishmaniasis.** (ClinExpImmunol. 1997;110(2):203-11)
  
- 70.** Rafati S., Couty-Jouv S., Dowlati Y. and Alimohammadian M.H. **Evaluation of cellular immune responses of recovered human cutaneous leishmaniasis to amastigote soluble *L. major* antigen.** (Medical Journal of the Islamic Republic of Iran. 1997;11(1):33-38)